Exact Sciences (EXAS) Expected to Announce Quarterly Earnings on Thursday

Exact Sciences (NASDAQ:EXAS - Get Free Report) will likely be releasing its Q1 2025 earnings data after the market closes on Thursday, May 1st. Analysts expect the company to announce earnings of ($0.35) per share and revenue of $688.58 million for the quarter. Exact Sciences has set its FY 2025 guidance at EPS.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last announced its earnings results on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.23. The company had revenue of $713.42 million for the quarter, compared to the consensus estimate of $701.45 million. Exact Sciences had a negative return on equity of 5.29% and a negative net margin of 37.29%. On average, analysts expect Exact Sciences to post $-1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Exact Sciences Price Performance

Shares of NASDAQ EXAS traded down $0.68 during trading on Tuesday, hitting $44.91. 250,399 shares of the company were exchanged, compared to its average volume of 2,594,202. Exact Sciences has a 1 year low of $39.97 and a 1 year high of $72.83. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.15 and a quick ratio of 1.93. The company has a market cap of $8.34 billion, a price-to-earnings ratio of -8.05 and a beta of 1.14. The firm's fifty day moving average price is $45.24 and its 200 day moving average price is $53.84.

Analysts Set New Price Targets

A number of brokerages recently weighed in on EXAS. Royal Bank of Canada started coverage on Exact Sciences in a report on Thursday, March 13th. They issued a "sector perform" rating and a $52.00 target price on the stock. Piper Sandler dropped their price target on shares of Exact Sciences from $75.00 to $70.00 and set an "overweight" rating for the company in a research note on Wednesday, February 26th. Scotiabank lifted their price objective on shares of Exact Sciences from $70.00 to $73.00 and gave the stock a "sector outperform" rating in a report on Monday, February 24th. Mizuho started coverage on Exact Sciences in a research report on Thursday, April 10th. They set an "outperform" rating and a $60.00 price objective for the company. Finally, William Blair reiterated an "outperform" rating on shares of Exact Sciences in a research report on Thursday, February 20th. Two equities research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $69.25.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.